BlackRock, Inc. Adds to CytomX Therapeutics Inc (CTMX) Stake -- Shares Look 1007% Overvalued on GF Value
BlackRock, Inc. increased its stake in CytomX Therapeutics Inc (CTMX) by 216.58% on June 30, 2026, purchasing 11,323,172 additional shares at $3.75 each, despite the stock being deemed significantly overvalued by GuruFocus. As of August 1, 2026, CTMX shares had dropped to $3.10, resulting …